---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-260299"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2023-10-23T23:59:59+00:00"
generated_at: "2026-06-09T16:45:59.233657+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines reports Phase 1/1b data for RMC-6236 in NSCLC and PDAC; plans Phase 3 in 2024

## Summary
- RMC-6236 showed ORR 38% (DCR 85%) in evaluable NSCLC (n=40) and ORR 20% (DCR 87%) in PDAC (n=46) as of Oct 12, 2023.
- Safety at ≥80 mg daily: mostly Grade 1-2 rash/GI events; one Grade 4 perforation led to discontinuation; no fatal TRAEs.
- Company plans global randomized Phase 3 trial of RMC-6236 vs docetaxel in RAS-mutated NSCLC, aiming to start in 2024.
- Potential Phase 3 vs physician's choice in PDAC and combo pivotal trials also planned, pending further data and regulatory feedback.
- RMC-4630 combo with sotorasib showed additive toxicity without sufficient benefit; no further development for that combination.

## SEC filing metadata
- accession: 0001193125-23-260299
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2023-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312523260299/0001193125-23-260299-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312523260299/d567415d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-260299
- JSON: https://secwatch.observer/filing/0001193125-23-260299.json
- Plain text: https://secwatch.observer/filing/0001193125-23-260299.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.